Catalyst Wire Dossier Catalyst Wire Dossier

Tagrisso (osimertinib)

osimertinib · AstraZeneca
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Tagrisso (osimertinib), covering 2024-11-12 to 2025-03-28. Get the full timeline:

Most recent: Clinical Trial Update: Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors [Phase 2]

See pricing